- Home
- TARS vs ULCC Comparison
TARS vs ULCC Comparison
Compare TARS & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- ULCC
- Stock Information
- Founded
- TARS 2016
- ULCC 1994
- Country
- TARS United States
- ULCC United States
- Employees
- TARS N/A
- ULCC N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- ULCC Air Freight/Delivery Services
- Sector
- TARS Health Care
- ULCC Consumer Discretionary
- Exchange
- TARS Nasdaq
- ULCC Nasdaq
- Market Cap
- TARS 1.8B
- ULCC 1.5B
- IPO Year
- TARS 2020
- ULCC 2021
- Fundamental
- Price
- TARS $44.83
- ULCC $6.80
- Analyst Decision
- TARS Strong Buy
- ULCC Hold
- Analyst Count
- TARS 5
- ULCC 11
- Target Price
- TARS $54.20
- ULCC $6.35
- AVG Volume (30 Days)
- TARS 1.1M
- ULCC 2.3M
- Earning Date
- TARS 11-13-2024
- ULCC 10-29-2024
- Dividend Yield
- TARS N/A
- ULCC N/A
- EPS Growth
- TARS N/A
- ULCC N/A
- EPS
- TARS N/A
- ULCC N/A
- Revenue
- TARS $129,621,000.00
- ULCC $3,664,000,000.00
- Revenue This Year
- TARS $852.60
- ULCC $6.19
- Revenue Next Year
- TARS $74.21
- ULCC $14.64
- P/E Ratio
- TARS N/A
- ULCC N/A
- Revenue Growth
- TARS 801.96
- ULCC 1.66
- 52 Week Low
- TARS $15.60
- ULCC $2.79
- 52 Week High
- TARS $52.99
- ULCC $8.33
- Technical
- Relative Strength Index (RSI)
- TARS 57.98
- ULCC 60.85
- Support Level
- TARS $46.22
- ULCC $6.42
- Resistance Level
- TARS $52.99
- ULCC $7.21
- Average True Range (ATR)
- TARS 3.62
- ULCC 0.42
- MACD
- TARS -0.33
- ULCC -0.02
- Stochastic Oscillator
- TARS 42.09
- ULCC 74.21
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers.